FGF13 promotes metastasis of triple-negative breast cancer

Cameron N Johnstone; Andrew D Pattison; Paul F Harrison; David R Powell; Peter Lock; Matthias Ernst; Robin L Anderson; Traude H Beilharz

Journal article

FGF13 promotes metastasis of triple-negative breast cancer

Cameron N Johnstone, Andrew D Pattison, Paul F Harrison, David R Powell, Peter Lock, Matthias Ernst, Robin L Anderson, Traude H Beilharz

INTERNATIONAL JOURNAL OF CANCER | WILEY | Published : 2020

DOI: 10.1002/ijc.32874

Download PDF

Abstract

Triple-negative breast cancer (TNBC) represents 10-20% of all human ductal adenocarcinomas and has a poor prognosis relative to other subtypes, due to the high propensity to develop distant metastases. Hence, new molecular targets for therapeutic intervention are needed for TNBC. We recently conducted a rigorous phenotypic and genomic characterization of four isogenic populations of MDA-MB-231 human triple-negative breast cancer cells that possess a range of intrinsic spontaneous metastatic capacities in vivo, ranging from nonmetastatic (MDA-MB-231_ATCC) to highly metastatic to lung, liver, spleen and spine (MDA-MB-231_HM). Gene expression profiling of primary tumours by RNA-Seq identified t..

View full abstract

University of Melbourne Researchers

Matthias Ernst Author Surgery - Royal Melbourne Hospital

Cameron Johnstone Author Clinical Pathology

Robin Anderson Author The Sir Peter MacCallum Department of Oncology

Related Projects (2)

A functional in vivo shRNA screen for regulators of breast cancer metastasis.

Breast cancer is generally incurable if detected after the tumour has spread to other organs. The genes driving the tumour cells to other si..

Control of the spread of breast cancer by small RNA molecules

When breast cancer spreads to other organs, it results in high morbidity and mortality. MicroRNAs are a class of genes that control the expr..

Grants

Awarded by Cass Foundation of Victoria (Australia)

Awarded by National Health and Medical Research Council (Australia)

Funding Acknowledgements

Our study was supported by a Cass Foundation of Victoria (Australia) Grant #SM/14/5567 (to C.N.J.), and National Health and Medical Research Council (Australia) project grants APP1128250 and APP1042848 (to T.H.B.), and APP1050384 and APP1020280 (to R.L.A.). We would like to thank the Animal Core Facility, Flow Cytometry Core Facility, and Centre for Advanced Histology and Microscopy (CAHM) at the Peter MacCallum Cancer Centre for services provided. We would also like to thank the Victorian Centre for Functional Genomics (VCFG) for the provision of pGIPZ lentiviral vectors, Sue Sturrock and Stephen Fox (Anatomical Pathology, Peter Mac) for immunohistochemistry services, Elaine Sanij and Richard Pearson (Peter Mac) for nucleophosmin/B23 and fibrillarin antibodies. Joan Massague (Memorial Sloan Kettering Cancer Centre) provided the MDA-MB-231_LM2 cell line and ZM Shao and ZL Ou (Breast Cancer Institute, Fudan University, Shanghai) provided the MDA-MB-231HM cell line. We thank Judy Doherty (Peter Mac) for generation of the 231_LNA cell line and David Baloyan (ONJCRI) for assistance with flow cytometry and cell cycle analysis.